IMMIX BIOPHARMA INC (IMMX)
Health Care · CAR-T cell therapy / cellular immunotherapy · NASDAQ
Immix Biopharma is a clinical-stage CAR-T cell therapy company developing next-generation immunotherapies for relapsed/refractory light chain amyloidosis with FDA Breakthrough Therapy designation.
What IMMIX BIOPHARMA INC does
Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR-T) cell therapies for light chain (AL) amyloidosis and other serious diseases. The company's lead candidate, NXC-201, is being evaluated in Phase 1b/2 clinical trials in both the United States and internationally. NXC-201 has received FDA Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy (RMAT) designation, and Orphan Drug designation for relapsed/refractory AL amyloidosis treatment.
Themes: ["CAR-T cell therapy","AL amyloidosis / light chain amyloidosis treatment","Regenerative medicine / cell therapy","Orphan drugs / rare disease"]
Fundamentals
- Price$11.09 as of 2026-07-09 close
- Market cap$789M as of 2026-07-10
- 1-year return+313.5% as of 2026-07-09 close
- ROE-73.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.06 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial risk: Success, cost, and timing of Phase 1b/2 NEXICART-2 and NEXICART-1 clinical trials are uncertain, with no guarantee of efficacy or safety outcomes meeting regulatory approval standards","Regulatory and capital risk: Company requires substantial additional capital to fund operations and clinical development; ability to maintain Nasdaq listing depends on meeting continued listing standards; regulatory approval by FDA for BLA submission is not assured","Manufacturing and third-party dependence: Reliance on third-party suppliers and manufacturers for cell therapy production; operational disruptions or supply chain failures could delay or halt clinical trials and commercialization"]
Competitors & peers
- Juno Therapeutics
- Gilead Sciences (GILD)
- Kite Pharma (subsidiary of Gilead)
- Celgene / Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Bluebird Bio
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.